Equities

CogState Ltd

CGS:ASX

CogState Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.96
  • Today's Change-0.015 / -1.54%
  • Shares traded8.95k
  • 1 Year change-38.26%
  • Beta0.7089
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Cogstate Ltd share price to rise to 1.44 in the next year from the last price of 0.96.
High49.8%1.44
Med49.8%1.44
Low49.8%1.44

Dividends

Dividend information is not available for CogState Ltd.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

Cogstate Ltd reported annual 2024 earnings of 0.032 per share on Aug 21, 2024.
Average growth rate+16.61%
More ▼

Revenue history & estimates in USD

Cogstate Limited had revenues for the full year 2024 of 43.43m. This was 5.53% above the prior year's results.
Average growth rate+17.17%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.